<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Novavax Inc — News on 6ix</title>
<link>https://6ix.com/company/novavax-inc</link>
<description>Latest news and press releases for Novavax Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 30 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/novavax-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a42378dffbe2df10a86e.webp</url>
<title>Novavax Inc</title>
<link>https://6ix.com/company/novavax-inc</link>
</image>
<item>
<title>Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development</title>
<link>https://6ix.com/company/novavax-inc/news/novavax-appoints-dr-robert-walker-as-executive-vice-president-and-head-of-research-and-development</link>
<guid isPermaLink="true">https://6ix.com/company/novavax-inc/news/novavax-appoints-dr-robert-walker-as-executive-vice-president-and-head-of-research-and-development</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical OfficerDr. Walker will</description>
</item>
<item>
<title>Nuvaxovid (Novavax) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F</title>
<link>https://6ix.com/company/novavax-inc/news/nuvaxovid-novavax-market-research-report-2026-epidemiology-pipeline-analysis-trends-strategies-and-forecasts-2020-2025-2025-2030f-2035f</link>
<guid isPermaLink="true">https://6ix.com/company/novavax-inc/news/nuvaxovid-novavax-market-research-report-2026-epidemiology-pipeline-analysis-trends-strategies-and-forecasts-2020-2025-2025-2030f-2035f</guid>
<pubDate>Fri, 13 Mar 2026 11:25:00 GMT</pubDate>
<description>The Nuvaxovid market offers opportunities in booster immunizations, variant-adapted vaccines, and increased global vaccine coverage. Trends include protein-based platforms, adjuvant-enhanced vaccines, and cold-chain distribution. Challenges like tariffs drive domestic manufacturing, while demand rises due to infectious disease prevalence.Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Nuvaxovid Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to Re</description>
</item>
<item>
<title>Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights</title>
<link>https://6ix.com/company/novavax-inc/news/novavax-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/novavax-inc/news/novavax-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areasMultiple Material Transfer Agreements</description>
</item>
<item>
<title>Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026</title>
<link>https://6ix.com/company/novavax-inc/news/novavax-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026</link>
<guid isPermaLink="true">https://6ix.com/company/novavax-inc/news/novavax-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026</guid>
<pubDate>Thu, 19 Feb 2026 05:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and full year 2025 financial</description>
</item>
<item>
<title>Novavax Announces Entering into a License Agreement with Pfizer</title>
<link>https://6ix.com/company/novavax-inc/news/novavax-announces-entering-license-agreement-121500992</link>
<guid isPermaLink="true">https://6ix.com/company/novavax-inc/news/novavax-announces-entering-license-agreement-121500992</guid>
<pubDate>Tue, 20 Jan 2026 12:15:00 GMT</pubDate>
<description>Novavax, Inc. (Nasdaq: NVAX) has entered into a license agreement with Pfizer for use of Novavax's Matrix-M® adjuvant. Under the terms of the agreement, Pfizer will obtain a non-exclusive license for Matrix-M for use with Pfizer's products in up to two disease areas.</description>
</item>
<item>
<title>Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/novavax-inc/news/novavax-participate-44th-annual-jp-morgan-healthcare-conference-2026-01-07</link>
<guid isPermaLink="true">https://6ix.com/company/novavax-inc/news/novavax-participate-44th-annual-jp-morgan-healthcare-conference-2026-01-07</guid>
<pubDate>Wed, 07 Jan 2026 05:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Jan. 7, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the 44th Annual J.P. Morgan</description>
</item>
<item>
<title>Novavax to Participate in Jefferies London Healthcare Conference</title>
<link>https://6ix.com/company/novavax-inc/news/novavax-participate-jefferies-london-healthcare-conference-2025-11-12</link>
<guid isPermaLink="true">https://6ix.com/company/novavax-inc/news/novavax-participate-jefferies-london-healthcare-conference-2025-11-12</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Nov. 12, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor</description>
</item>
<item>
<title>Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights</title>
<link>https://6ix.com/company/novavax-inc/news/novavax-reports-third-quarter-2025-financial-results-and-operational-highlights-2025</link>
<guid isPermaLink="true">https://6ix.com/company/novavax-inc/news/novavax-reports-third-quarter-2025-financial-results-and-operational-highlights-2025</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Total revenue of $70 million in the third quarter of 2025 Continued successful execution of Sanofi partnership with $225 million in milestones achieved</description>
</item>
<item>
<title>Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment</title>
<link>https://6ix.com/company/novavax-inc/news/novavax-completes-us-marketing-authorization-transfer-sanofi-nuvaxovidtm-triggering</link>
<guid isPermaLink="true">https://6ix.com/company/novavax-inc/news/novavax-completes-us-marketing-authorization-transfer-sanofi-nuvaxovidtm-triggering</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Novavax has successfully achieved U.S. BLA approval and completed both EU and U.S. marketing authorization transfers for Nuvaxovid™ to Sanofi in line with</description>
</item>
<item>
<title>Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025</title>
<link>https://6ix.com/company/novavax-inc/news/novavax-report-third-quarter-2025-financial-results-november-6-2025-2025-10-30</link>
<guid isPermaLink="true">https://6ix.com/company/novavax-inc/news/novavax-report-third-quarter-2025-financial-results-november-6-2025-2025-10-30</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Oct. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its third quarter 2025 financial results and</description>
</item>
<item>
<title>Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy</title>
<link>https://6ix.com/company/novavax-inc/news/novavax-executes-planned-site-consolidation-further-reducing-cost-footprint-line</link>
<guid isPermaLink="true">https://6ix.com/company/novavax-inc/news/novavax-executes-planned-site-consolidation-further-reducing-cost-footprint-line</guid>
<pubDate>Wed, 22 Oct 2025 04:00:00 GMT</pubDate>
<description>Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230</description>
</item>
<item>
<title>Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment</title>
<link>https://6ix.com/company/novavax-inc/news/novavax-continues-deliver-sanofi-partnership-completing-nuvaxovidr-eu-marketing</link>
<guid isPermaLink="true">https://6ix.com/company/novavax-inc/news/novavax-continues-deliver-sanofi-partnership-completing-nuvaxovidr-eu-marketing</guid>
<pubDate>Tue, 07 Oct 2025 04:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Oct. 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19</description>
</item>
<item>
<title>Novavax Announces Progress on Sanofi Agreement</title>
<link>https://6ix.com/company/novavax-inc/news/novavax-announces-progress-sanofi-agreement-2025-09-30</link>
<guid isPermaLink="true">https://6ix.com/company/novavax-inc/news/novavax-announces-progress-sanofi-agreement-2025-09-30</guid>
<pubDate>Tue, 30 Sep 2025 04:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Sept. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration and license agreement (CLA) with</description>
</item>
<item>
<title>Nuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment</title>
<link>https://6ix.com/company/novavax-inc/news/nuvaxovidr-now-approved-japan-triggering-takeda-milestone-payment-2025-09-04</link>
<guid isPermaLink="true">https://6ix.com/company/novavax-inc/news/nuvaxovidr-now-approved-japan-triggering-takeda-milestone-payment-2025-09-04</guid>
<pubDate>Thu, 04 Sep 2025 04:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Sept. 4, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced a milestone payment* from Takeda has been triggered by</description>
</item>
<item>
<title>Novavax to Participate in the Cantor Global Healthcare Conference</title>
<link>https://6ix.com/company/novavax-inc/news/novavax-participate-cantor-global-healthcare-conference-2025-09-03</link>
<guid isPermaLink="true">https://6ix.com/company/novavax-inc/news/novavax-participate-cantor-global-healthcare-conference-2025-09-03</guid>
<pubDate>Wed, 03 Sep 2025 04:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Sept. 3, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor</description>
</item>
<item>
<title>Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.</title>
<link>https://6ix.com/company/novavax-inc/news/novavaxs-nuvaxovidtm-2025-2026-formula-covid-19-vaccine-approved-us-2025-08-27</link>
<guid isPermaLink="true">https://6ix.com/company/novavax-inc/news/novavaxs-nuvaxovidtm-2025-2026-formula-covid-19-vaccine-approved-us-2025-08-27</guid>
<pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
<description>Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination seasonGAITHERSBURG, Md., Aug. 27, 2025</description>
</item>
<item>
<title>Novavax Announces Convertible Debt Refinancing</title>
<link>https://6ix.com/company/novavax-inc/news/novavax-announces-convertible-debt-refinancing-2025-08-21</link>
<guid isPermaLink="true">https://6ix.com/company/novavax-inc/news/novavax-announces-convertible-debt-refinancing-2025-08-21</guid>
<pubDate>Thu, 21 Aug 2025 04:00:00 GMT</pubDate>
<description>Refinancing extends maturity of most existing debt with improved terms$225 million of convertible notes due in 2031 issued, including a ~$175 million exchange</description>
</item>
<item>
<title>Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights</title>
<link>https://6ix.com/company/novavax-inc/news/novavax-reports-second-quarter-2025-financial-results-and-operational-highlights-2025</link>
<guid isPermaLink="true">https://6ix.com/company/novavax-inc/news/novavax-reports-second-quarter-2025-financial-results-and-operational-highlights-2025</guid>
<pubDate>Wed, 06 Aug 2025 04:00:00 GMT</pubDate>
<description>Total revenue of $239 million in the second quarter of 2025Received FDA BLA approval for Nuvaxovid™, the only recombinant protein-based, non-mRNA COVID-19</description>
</item>
<item>
<title>Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025</title>
<link>https://6ix.com/company/novavax-inc/news/novavax-report-second-quarter-2025-financial-results-august-6-2025-2025-07-30</link>
<guid isPermaLink="true">https://6ix.com/company/novavax-inc/news/novavax-report-second-quarter-2025-financial-results-august-6-2025-2025-07-30</guid>
<pubDate>Wed, 30 Jul 2025 04:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., July 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its second quarter 2025 financial results and</description>
</item>
<item>
<title>Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study</title>
<link>https://6ix.com/company/novavax-inc/news/novavaxs-h5n1-vaccine-candidate-demonstrates-immunogenicity-preclinical-study-2025-07</link>
<guid isPermaLink="true">https://6ix.com/company/novavax-inc/news/novavaxs-h5n1-vaccine-candidate-demonstrates-immunogenicity-preclinical-study-2025-07</guid>
<pubDate>Thu, 24 Jul 2025 04:00:00 GMT</pubDate>
<description>Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or</description>
</item>
</channel>
</rss>